Dihydroergotamine (Mesylate)

Also known as: Dihydroergotamine mesylate dihydergot, Orstanorm, DHE45, Dihydrocorgotamine-sandaz

Drug #243

Dihydroergotamine (Mesylate) is antiadrenergic produced by the catalytic hydrogenation of ergotamine. Dihydroergotamine (Mesylate) is a smooth muscle stimulant. Dihydroergotamine (Mesylate) is a derivative of ergotamine and is used to treat migraine headache attack.

← Previous drug Next drug →

Primary Characteristics

Dihydroergotamine (Mesylate) is also known as Dihydroergotamine mesylate dihydergot, Orstanorm, DHE45, Dihydrocorgotamine-sandaz.

It is of Semi Synthetic origin and belongs to Ergot Alkaloid.

It belongs to 5HT-1 agonist , Alpha adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Vasoconstrictor pharmacological group. It is also classified under Analgesics and Anti-inflammatory Agents .

Molecular Weight: 679.8 · pK_a: 6.35 · Solubility in Water: 1 in 125 · Solubility in Alcohol: 1 in 90 · Non-proprietary name: Dihydroergotamine (Mesylate).

Molecular structure of Dihydroergotamine (Mesylate)

Pharmacokinetics

Absorption: Dihydroergotamine (Mesylate) has an oral bioavailability is 34.6% (±25.7%), pre-systemic (first-pass) metabolism accounts for 99%.

Distribution: Dihydroergotamine (Mesylate) has a volume of distribution is 5.6-30 l/kg(800 L). plasma protein binding is 90-93%.

Elimination: it is metabolised via extensive by Liver, plasma half-life is 1-2 hr, renal excretion is 6-7%.

Indications

Dihydroergotamine (Mesylate) is primarily indicated in conditions like Cluster headache, Migraine, Migraine prophylaxis, Vascular headaches.

Dihydroergotamine (Mesylate) is also indicated for secondary conditions like Orthostatic hypotension.

Contraindications

Dihydroergotamine (Mesylate) is contraindicated in conditions like Hypertension, Shock, Septicaemia, Coronary insufficiency.

Dosage

Dihydroergotamine (Mesylate)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.014 mg/kg	0.014 mg/kg	—	IM	Maint, As Req, after 30-60 Min of the Initial Dose
0.021 mg/kg	0.021 mg/kg	—	IM	Initially for Once
0.014 mg/kg	0.014 mg/kg	—	SC	Maint, As Req, after 30-60 Min of the Initial Dose
0.021 mg/kg	0.021 mg/kg	—	SC	Initially for Once
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

Unknown5 interactions

2 interactions

Major3 interactions

Moderate1 interaction

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Dihydroergotamine (Mesylate) in overdosage may give rise to further complications which include Renal insufficiency.

Dihydroergotamine (Mesylate) produces potentially life-threatening effects which include Coronary spasm, Anginal pain. Careful monitoring is needed with proper medical management.

The signs and symptoms that are produced after acute overdosage of Dihydroergotamine (Mesylate) are Vomiting, ECG alterations, Headache, Peripheral vasoconstriction, Acrocyanosis, Rise in B.P. .

Dihydroergotamine (Mesylate) is known to cause more or less tolerable side effects which are usually transient. These include Bradycardia , Nausea and vomiting, Numbness , Precordial pain, Tachycardia, Tingling of the fingers and toes.

Warnings / Precautions

Avoid prolong administration or excessive dosage of dihydroergotamine because of danger of gangrene, ergotism and patients become dependent upon it.

Available Brands

None recorded.

Storage Conditions

Dihydroergotamine (Mesylate) should be stored Aerosol.

Drug Classification

1.7.1 — Acute migraine attack